Volume 2, Issue 2 (Spring 2021)
J Vessel Circ 2021, 2(2): 63-68 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Saberi A, Elahi A, Jalali M T, Latif S M. Plasma Cell-free DNA Levels in Children With Acute Lymphoblastic Leukemia. J Vessel Circ 2021; 2 (2) :63-68
URL: http://jvessels.muq.ac.ir/article-1-71-en.html
URL: http://jvessels.muq.ac.ir/article-1-71-en.html
1- Department of Medical genetic, Faculty of Medicine, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran, jundishapour university of Medical Sciences
2- Department of Medical Technology, Faculty of Paramedicine, Qom University of Medical Sciences, Qom, Iran., Qom University of Medical Sciences
3- Department of Medical Technology, Faculty of Paramedicine ,Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran, jundishapour university of Medical Sciences
2- Department of Medical Technology, Faculty of Paramedicine, Qom University of Medical Sciences, Qom, Iran., Qom University of Medical Sciences
3- Department of Medical Technology, Faculty of Paramedicine ,Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran, jundishapour university of Medical Sciences
Abstract: (928 Views)
Background and Aim: Plasma levels of cell-free DNA (cfDNA) are elevated in various clinical conditions, including cancer, myocardial infarction, autoimmune disease, and pregnancy-associated complications. The aim of this study was to determine the level of cfDNA to assess the potential of cfDNA as a biomarker for screening and diagnosis and also its effectiveness in the treatment of patients with acute lymphoblastic leukemia (ALL).
Materials and Methods: Overall, 40 individuals (20 healthy volunteers and 20 patients with ALL) were examined. For quantitative analysis of cfDNA, plasma purified DNA was subjected to real-time PCR amplification of the beta-globin gene. Quantification of cfDNA levels was performed at the time of diagnosis and after treatment with a common protocol.
Results: At diagnosis, in all samples, plasma levels of cfDNA were significantly elevated compared to those of healthy controls after treatment. The high levels of cfDNA decreased and returned to normal after treatment.
Conclusion: Data showed that despite the significant cfDNA concentration increment in patients than the control group, its detection and treatment potential should be more studied: however, it still can be a useful marker for screening of diseases, such as hematological neoplasms.
Materials and Methods: Overall, 40 individuals (20 healthy volunteers and 20 patients with ALL) were examined. For quantitative analysis of cfDNA, plasma purified DNA was subjected to real-time PCR amplification of the beta-globin gene. Quantification of cfDNA levels was performed at the time of diagnosis and after treatment with a common protocol.
Results: At diagnosis, in all samples, plasma levels of cfDNA were significantly elevated compared to those of healthy controls after treatment. The high levels of cfDNA decreased and returned to normal after treatment.
Conclusion: Data showed that despite the significant cfDNA concentration increment in patients than the control group, its detection and treatment potential should be more studied: however, it still can be a useful marker for screening of diseases, such as hematological neoplasms.
Type of Study: Research |
Subject:
hematology
Received: 2021/05/3 | Accepted: 2021/10/2 | Published: 2021/12/1
Received: 2021/05/3 | Accepted: 2021/10/2 | Published: 2021/12/1
References
1. Dwivedi DJ, Toltl LJ, Swystun LL, Pogue J, Liaw KL, Weitz JI, et al. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Critical Care. 2012; 16(4):R151. [DOI:10.1186/cc11466] [PMID] [PMCID] [DOI:10.1186/cc11466]
2. Gahan PB, Swaminathan R. Circulating nucleic acids in plasma and serum. Recent developments. Ann N Y Acad Sci. 2008; 1137:1-6. [DOI:10.1196/annals.1448.050] [PMID] [DOI:10.1196/annals.1448.050]
3. Ozkaya O, Bek K, Bedir A, Açikgöz Y, Ozdemir T. Plasma cell-free DNA levels in children on peritoneal dialysis. Nephron Clin Pract. 2009; 113(4):c258-61. [DOI:10.1159/000235250] [PMID] [DOI:10.1159/000235250]
4. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids--A promising, non-invasive tool for early detection of several human diseases. FEBS Lett. 2007; 581(5):795-9. [DOI:10.1016/j.febslet.2007.01.051] [PMID] [DOI:10.1016/j.febslet.2007.01.051]
5. Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. Cancer Treat Rev. 2014; 40(5):648-55. [DOI:10.1016/j.ctrv.2013.10.003] [PMID] [DOI:10.1016/j.ctrv.2013.10.003]
6. Ryan BM, Lefort F, McManus R, Daly J, Keeling PW, Weir DG, et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: Strong prognostic indicator in postoperative follow up. Gut. 2003; 52(1):101-8. [DOI:10.1136/gut.52.1.101] [PMID] [PMCID] [DOI:10.1136/gut.52.1.101]
7. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994; 3(1):67-71. [PMID]
8. Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology. 1997; 112:1114-20. [DOI:10.1016/S0016-5085(97)70121-5] [DOI:10.1016/S0016-5085(97)70121-5]
9. Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996; 2(9):1033-5. [DOI:10.1038/nm0996-1033] [PMID] [DOI:10.1038/nm0996-1033]
10. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996; 2(9):1035-7. [DOI:10.1038/nm0996-1035] [PMID] [DOI:10.1038/nm0996-1035]
11. Goessl C, Heicappell R, Münker R, Anker P, Stroun M, Krause H, et al. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res. 1998; 58(20):4728-32. [PMID]
12. Fujiwara Y, Chi DD, Wang H, Keleman P, Morton DL, Turner R, et al. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res. 1999; 59(7):1567-71. [PMID]
13. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, et al. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004; 22(20):4157-64. [DOI:10.1200/JCO.2004.11.123] [PMID] [DOI:10.1200/JCO.2004.11.123]
14. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer. 2007; 97(10):1399-403. [DOI:10.1038/sj.bjc.6604034] [PMID] [PMCID] [DOI:10.1038/sj.bjc.6604034]
15. Rogers A, Joe Y, Manshouri T, Dey A, Jilani I, Giles F, et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood. 2004; 103(7):2799-801. [DOI:10.1182/blood-2003-06-1840] [PMID] [DOI:10.1182/blood-2003-06-1840]
16. Schwarz AK, Stanulla M, Cario G, Flohr T, Sutton R, Möricke A, et al. Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Ann Hematol. 2009; 88(9):897-905. [DOI:10.1007/s00277-009-0698-6] [PMID] [DOI:10.1007/s00277-009-0698-6]
17. Yeh P, Dickinson M, Ftouni S, Hunter T, Sinha D, Wong SQ, et al. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood. 2017; 129(12):1685-90. [DOI:10.1182/blood-2016-09-740308] [PMID] [DOI:10.1182/blood-2016-09-740308]
18. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol. 2009; 20(8):1408-13. [DOI:10.1093/annonc/mdp006] [PMID] [DOI:10.1093/annonc/mdp006]
19. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):83-103. [DOI:10.3322/caac.21219] [PMID] [DOI:10.3322/caac.21219]
20. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003; 21(21):3902-8. [DOI:10.1200/JCO.2003.02.006] [PMID] [DOI:10.1200/JCO.2003.02.006]
21. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998; 62(4):768-75. [PMID] [DOI:10.1086/301800]
22. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2007; 1775(1):181-232. [DOI:10.1016/j.bbcan.2006.10.001] [PMID] [DOI:10.1016/j.bbcan.2006.10.001]
23. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: A new diagnostic gold mine? Cancer Treat Rev. 2002; 28(5):255-71. [DOI:10.1016/S0305-7372(02)00077-4] [DOI:10.1016/S0305-7372(02)00077-4]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2717-0357
Email: jvessels[at]muq.ac.ir
j.vessels.circul[at]gmail.com
